Ivonescimab Combination with Chemotherapy Receives NMPA Approval in China for EGFRm NSCLC
Ivonescimab Combination with Chemotherapy Approval in China for EGFRm NSCLC
A recent development in the field of oncology has been the approval by the NMPA in China for the use of Ivonescimab in combination with chemotherapy for patients with EGFRm NSCLC. This approval is based on the positive results observed in the HARMONi-A clinical trial.
Positive Survival Trend towards Ivonescimab Plus Chemo
One of the key findings from the trial includes a positive trend in overall survival rates among patients receiving Ivonescimab combined with chemotherapy. This indicates the potential of this treatment approach in improving patient outcomes and extending survival.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.